Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence (SENSE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00811941 |
Recruitment Status :
Completed
First Posted : December 19, 2008
Results First Posted : August 7, 2013
Last Update Posted : August 7, 2013
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Alcohol Dependence | Drug: Placebo Drug: Nalmefene | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 665 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Safety, Tolerability and Efficacy Study of Nalmefene, as Needed Use, in Patients With Alcohol Dependence |
Study Start Date : | March 2009 |
Actual Primary Completion Date : | November 2010 |
Actual Study Completion Date : | November 2010 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo |
Drug: Placebo
as-needed use, tablets, orally, 52 weeks |
Experimental: Nalmefene |
Drug: Nalmefene
18.06 mg as-needed use, tablets, orally, 52 weeks. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
Other Name: Selincro™ |
- Number of Patients With Adverse Events (AEs) [ Time Frame: Serious Adverse Events: 52 weeks and a safety follow-up (visit/telephone call) scheduled for 4 weeks after completion of the study or after withdrawal from the study. Other Adverse Events: 52 weeks. ]Overview of AEs
- Percentage of Patients Who Withdrew Due to Intolerance to Treatment [ Time Frame: Baseline to Week 52 ]
- Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs) [ Time Frame: Baseline and Month 6 ]Number of HDDs over a month (28 days), where one HDD was defined as a day with alcohol consumption ≥60 grams (g) for men and ≥40 g for women.
- Change From Baseline in the Monthly Total Alcohol Consumption (TAC) [ Time Frame: Baseline and Month 6 ]TAC was defined as mean daily alcohol consumption in g/day over a month (28 days).
- Drinking Risk Level (RSDRL) Response [ Time Frame: Month 6 ]RSDRL response was defined as a downward shift from baseline in Drinking Risk Level (DRL); for patients at very high risk at Baseline: a shift to medium risk or below, and for patients at high or medium risk at Baseline: a shift to low risk or below.
- Change From Baseline in Clinical Status Using CGI-S [ Time Frame: Baseline and Week 24 ]The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).
- Change in Clinical Status Using the CGI-I [ Time Frame: Week 24 ]The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7- point scale ranging from 1 (very much improved) to 7 (very much worse).
- Liver Function Test Gamma-glutamyl Transferase (GGT) [ Time Frame: Week 24 ]GGT values
- Liver Function Test Alanine Aminotransferase (ALAT) [ Time Frame: Week 24 ]ALAT values
- Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs) [ Time Frame: Baseline and Month 13 ]Number of HDDs over a month (28 days), where one HDD was defined as a day with alcohol consumption ≥60 g for men and ≥40 g for women.
- Change From Baseline in the Monthly Total Alcohol Consumption (TAC) [ Time Frame: Baseline and Month 13 ]TAC was defined as mean daily alcohol consumption in g/day over a month (28 days).
- Drinking Risk Level (RSDRL) Response [ Time Frame: Month 13 ]RSDRL response was defined as a downward shift from baseline in Drinking Risk Level (DRL); for patients at very high risk at Baseline: a shift to medium risk or below, and for patients at high or medium risk at Baseline: a shift to low risk or below.
- Change From Baseline in Clinical Status Using CGI-S [ Time Frame: Baseline and Week 52 ]The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).
- Change in Clinical Status Using the CGI-I [ Time Frame: Week 52 ]The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7- point scale ranging from 1 (very much improved) to 7 (very much worse).
- Liver Function Test Gamma-glutamyl Transferase (GGT) [ Time Frame: Week 52 ]GGT values
- Liver Function Test Alanine Aminotransferase (ALAT) [ Time Frame: Week 52 ]ALAT values

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
In- and outpatients who:
- had a primary diagnosis of alcohol dependence according to Diagnostic and Statistical Manual of Mental Disorders - text revision (DSM-IV-TR) criteria
- had had ≥6 Heavy Drinking Days (HDDs) in the 4 weeks preceding the Screening Visit
Exclusion Criteria:
The patient:
- had a severe psychiatric disorder or an antisocial personality disorder
- had risk of suicide evaluated by the suicidality module of the Mini-International Neuropsychiatric Interview (MINI)
- had a history of delirium tremens or alcohol withdrawal seizures
- reported current or recent (within 3 months preceding screening) treatment with disulfiram, acamprosate, topiramate, naltrexone or carbimide, or with any opioid antagonists
- was pregnant or breast-feeding
Other protocol-defined inclusion and exclusion criteria may apply.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00811941

Study Director: | Email contact via H. Lundbeck A/S | LundbeckClinicalTrials@lundbeck.com |
Responsible Party: | H. Lundbeck A/S |
ClinicalTrials.gov Identifier: | NCT00811941 |
Other Study ID Numbers: |
12013A 2007-002315-92 ( EudraCT Number ) |
First Posted: | December 19, 2008 Key Record Dates |
Results First Posted: | August 7, 2013 |
Last Update Posted: | August 7, 2013 |
Last Verified: | July 2013 |
Pharmacologic Actions Alcohol-Related Disorders Alcoholism Mental Disorders Central Nervous System Agents |
Alcoholism Alcohol-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders |
Nalmefene Narcotic Antagonists Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents |